Home  >  TopNews
Msc_Jun22 Advertisement
you can get e-magazine links on WhatsApp. Click here
  SEC recommends protocol amendment for GSK's stalled RSV maternal vaccine trial,   June 24, 2022
  ICMR set to develop centres for phase I clinical trial,   June 13, 2022
  SEC asks Roche to submit documentary evidence and efficacy results on two indications of anti-cancer drug atezolizumab,   May 21, 2022
  SEC recommends granting permission to Novartis for phase III b trial of inclisiran,   May 19, 2022
  SEC asks SII and ICMR to submit combined view on approval of TB testing product C-Tb,   April 19, 2022
  Parliamentary panel asks ICMR to work with pharma industry to regain trust on clinical trials,   April 12, 2022
  DCGI calls on stakeholders to initiate clinical trials early to get market access to global drugs,   March 24, 2022
  Global pharma reinforces India’s clinical trial capability for CKD medicines,   March 10, 2022
  ICMR to conduct clinical trial for new drugs regimen for MDR TB,   February 21, 2022
  ICMR launches online portal to streamline submission of clinical trial applications for gene therapy,   February 14, 2022
  Data driven approach in clinical trials to aid identifying risks critical to patient safety: Ram Mudaliar,   February 07, 2022
  Sun Pharma gets SEC nod for phase III clinical trial for antipsychotic drug pimavanserin,   January 27, 2022
  Health ministry issues draft amendment to ND&CT Rules for deemed approval of clinical trials,   January 25, 2022
  Digital technologies to play key role in drug development by reducing timelines for approvals: ISCR,   November 03, 2021
  AIG Hospitals study on MAT proves 100% effective in preventing severe Covid disease and death,   November 03, 2021
  Natco and Hetero awaiting market authorization from DCGI on molnupiravir after submitting phase-3 trial data,   October 30, 2021
  ISCR continues to focus on promoting India’s capabilities in clinical research,   October 28, 2021
  Clinical trials are essential to validate healthcare machine learning models: Prasanth Madavana,   October 28, 2021
  SEC refuses local trial waiver for Novartis’ inclisiran injection, asks to submit phase III clinical trial protocol,   October 26, 2021
  Aurobindo & MSN seek SEC's nod to discontinue molnupiravir phase III studies on moderate Covid-19 patients,   October 09, 2021

Copyright © 2016 Saffron Media Pvt. Ltd |